Clinical Trials Logo

Gastrointestinal Cancer clinical trials

View clinical trials related to Gastrointestinal Cancer.

Filter by:

NCT ID: NCT04802486 Completed - Weight Loss Clinical Trials

The Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients With Cancers of the Gastrointestinal Tract With Pre- Cachexia or Cachexia

Start date: June 29, 2016
Phase: N/A
Study type: Interventional

The main purpose of this research study is to determine if exercise improve or worsen cachexia.

NCT ID: NCT04692454 Completed - Clinical trials for Gastrointestinal Cancer

Investigation of Immune Modulation by Modern Acupuncture in Gastroenterologic Cancers

Start date: August 31, 2020
Phase: N/A
Study type: Interventional

According to the total population of cancer patients, hepatocellular carcinoma (HCC) and colorectal cancer (CRC), two of gastroenterological cancers are involved in the most acquired five cancers. Colorectal cancer (CRC) is a leading cause of tumor-related morbidity and mortality worldwide, and HCC is one of the top ten cancers in China. Currently, the intervention for gastrointestinal cancers mainly focuses on surgical removal, but patients still have a high risk of recurrence. Thus, the prevention of cancer recurrence is the most crucial topic for the intervention. The pathophysiology of gastroenterological cancers is multifactorial and not yet completely understood. However, immunosuppression is a major contributing factor in tumor cells play a central part in disease progression. It determines the prognosis of patients.

NCT ID: NCT04680104 Completed - Clinical trials for Gastrointestinal Cancer

Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination With 5-Fluorouracil (5FU) /or in FOLFIRI Regimen

Start date: November 3, 2015
Phase:
Study type: Observational

Prospective observational study comparing calcium and sodium levofolinate in combination with 5FU/or in FOLFIRI regimen on patients affected by gastrointestinal cancer (any site of disease along with gastrointestinal tract) who have been prescribed FOLFIRI in standard clinical practice.

NCT ID: NCT04602611 Completed - Clinical trials for Gastrointestinal Cancer

Impact Of Nurse Navigation Program on Outcomes in Patients With GI Cancers

ACCESS
Start date: November 3, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to learn about the impact of the Oncology Nurse Navigation program on the frequency of Emergency Department, urgent care visits and inpatient hospital admissions; and overall survival rate at 6 months. The investigators aim to understand if prompt and effective coordination of care provided by Oncology Nurse Navigation (ONN) service will reduce the number of avoidable, unplanned ED visits and hospitalizations, as well as adding measurable value to cancer care, and improve patient overall survival.

NCT ID: NCT04566848 Completed - Clinical trials for Gastrointestinal Cancer

The Status of Immune Checkpoints at Gastrointestinal Cancer

Start date: August 1, 2020
Phase:
Study type: Observational

Colorectal cancers are the third most common cancer in the world. In advanced stages of colorectal cancers, peritoneal carcinomatosis and intraabdominal acid development occur. Although stomach cancer is the 5th most common cancer in the world, it is the third cancer with the highest mortality. Pancreatic cancer is one of the highest mortality cancers worldwide. Likewise, in advanced stages of stomach and pancreatic cancer, peritoneal carcinomatosis and intra- abdominal acid development occur. It is known that the immune system plays an important role in tumor development or destruction of tumor. Recent studies have shown that tumor cells develop escape mechanisms in the tumor microenvironment to escape from host immunity. It has been reported that differentiation of T cells towards Th2 and regulatory T cells is also effective in tumor progression(6). Changes in the tumor microenvironment and immune checkpoints are important mechanisms that lead to escape from the immune system. Immune checkpoints are on the agenda especially after 2018 Nobel Prize and they are important molecules in revealing the relationship.In our study, it is aimed to evaluate whether there is a difference in immune control points in patients with end-stage colorectal cancer, gastric cancer and pancreatic cancer compared to patients without malignancy, and the relationship of these parameters with patient survival and tumor spread mechanisms.

NCT ID: NCT04532515 Completed - Colon Cancer Clinical Trials

Seal-G / Seal-G MIST Study

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

A prospective, multi-center, open label, study to evaluate safety and performance of Seal-G and Seal-G MIST in reinforcing colonic anastomosis, in subjects undergoing Colon Resection surgery

NCT ID: NCT04201730 Completed - Clinical trials for Gastrointestinal Cancer

Study on the Efficacy and Safety of Enhanced Recovery After Surgery (ERAS)in Gastrointestinal Cancer

Start date: December 25, 2019
Phase: N/A
Study type: Interventional

At present, there are more and more reports about enhanced recovery after surgery(ERAS)in China, but there is no ERAS treatment standard for gastrointestinal cancer, and there are many factors limiting the development of ERAS. In recent years, due to the development of minimally invasive technology, the establishment of evidence-based medicine model and the development of MDT, it makes a good solid foundation for the clinical application of ERAS. The implementation of ERAS requires the cooperation of surgeons, anesthesia management, nursing, rehabilitation and other teams. As an individualized treatment mode, ERAS focuses on the optimization of treatment for different individuals in order to acquire the best benefit of patients. Therefore, the concept of ERAS is still in the process of continuous improvement and development in China, hoping to explore the Chinese ERAS clinical pathway for gastrointestinal cancer. The purpose of this study is to optimize the clinical pathway of ERAS in the perioperative period of gastrointestinal cancer, and to evaluate the effectiveness and safety of ERAS in gastrointestinal cancer.

NCT ID: NCT04131426 Completed - Lung Cancer Clinical Trials

Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia

Start date: April 24, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this research study is to determine if the use of a nutritional supplement and exercise improve or worsen cachexia.

NCT ID: NCT04081831 Completed - Clinical trials for Gastrointestinal Cancer

Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer

ENgAGE-HK
Start date: July 31, 2019
Phase:
Study type: Observational

In this study, researchers wanted to learn more about the effect of Aspirin taken as low dose (75 - 300 mg) in preventing stomach, colorectal and esophagus cancer. The researchers were interested in the effect by duration of aspirin use and the effect on the time since aspirin intake has been stopped in preventing stomach, colorectal and esophagus cancer. In addition, the study also looked into the time patients survived after being diagnosed (survival rate) with cancer and number of cancer patients who died (case fatality rate). The study was based on an electronic database managed by the Health Authority in Hong Kong containing anonymized clinical information of patients living in Hong Kong.

NCT ID: NCT03858855 Completed - Skin Cancer Clinical Trials

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

Start date: February 18, 2019
Phase: N/A
Study type: Interventional

This single-blind, randomized controlled trial studies how well inhaled essential oils work for common quality of life concerns in patients who are undergoing cancer treatment such as chemotherapy, targeted therapy, and/or immunotherapy given through the vein (intravenously). Aromatherapy using essential oils, such as ginger essential oil, German chamomile essential oil, and bergamot essential oil, may improve quality of life issues such as nausea, anxiety, loss of appetite, and fatigue in patients undergoing treatment for cancer.